<?xml version='1.0' encoding='utf-8'?>
<document id="27882176"><sentence text="Effect of the interaction between atorvastatin and selective serotonin reuptake inhibitors on the blood redox equilibrium."><entity charOffset="34-46" id="DDI-PubMed.27882176.s1.e0" text="atorvastatin" /><entity charOffset="61-70" id="DDI-PubMed.27882176.s1.e1" text="serotonin" /><pair ddi="false" e1="DDI-PubMed.27882176.s1.e0" e2="DDI-PubMed.27882176.s1.e0" /><pair ddi="false" e1="DDI-PubMed.27882176.s1.e0" e2="DDI-PubMed.27882176.s1.e1" /></sentence><sentence text="Cardiovascular disease and depression often occur simultaneously in the same patient" /><sentence text=" Long-term polypharmacotherapy can lead to drug-induced oxidative stress" /><sentence text=" Data concerning the effects of concomitant treatment with atorvastatin and selective serotonin reuptake inhibitors (SSRIs) are lacking"><entity charOffset="59-71" id="DDI-PubMed.27882176.s4.e0" text="atorvastatin" /><entity charOffset="86-95" id="DDI-PubMed.27882176.s4.e1" text="serotonin" /><pair ddi="false" e1="DDI-PubMed.27882176.s4.e0" e2="DDI-PubMed.27882176.s4.e0" /><pair ddi="false" e1="DDI-PubMed.27882176.s4.e0" e2="DDI-PubMed.27882176.s4.e1" /></sentence><sentence text=" The aim of the present study was to examine oxidative stress parameters in the blood of rats after 28 days treatment with atorvastatin combined with fluoxetine or paroxetine"><entity charOffset="123-135" id="DDI-PubMed.27882176.s5.e0" text="atorvastatin" /><entity charOffset="150-160" id="DDI-PubMed.27882176.s5.e1" text="fluoxetine" /><entity charOffset="164-174" id="DDI-PubMed.27882176.s5.e2" text="paroxetine" /><pair ddi="false" e1="DDI-PubMed.27882176.s5.e0" e2="DDI-PubMed.27882176.s5.e0" /><pair ddi="false" e1="DDI-PubMed.27882176.s5.e0" e2="DDI-PubMed.27882176.s5.e1" /><pair ddi="false" e1="DDI-PubMed.27882176.s5.e0" e2="DDI-PubMed.27882176.s5.e2" /><pair ddi="false" e1="DDI-PubMed.27882176.s5.e1" e2="DDI-PubMed.27882176.s5.e1" /><pair ddi="false" e1="DDI-PubMed.27882176.s5.e1" e2="DDI-PubMed.27882176.s5.e2" /></sentence><sentence text=" The study was carried out on male Wistar rats weighing 200-250 g" /><sentence text=" Aqueous solutions of atorvastatin (10 mg/kg), fluoxetine (10 mg/kg) and paroxetine (10 mg/kg) were injected once a day for 28 days, separately or concomitantly"><entity charOffset="22-34" id="DDI-PubMed.27882176.s7.e0" text="atorvastatin" /><entity charOffset="47-57" id="DDI-PubMed.27882176.s7.e1" text="fluoxetine" /><entity charOffset="73-83" id="DDI-PubMed.27882176.s7.e2" text="paroxetine" /><pair ddi="false" e1="DDI-PubMed.27882176.s7.e0" e2="DDI-PubMed.27882176.s7.e0" /><pair ddi="false" e1="DDI-PubMed.27882176.s7.e0" e2="DDI-PubMed.27882176.s7.e1" /><pair ddi="false" e1="DDI-PubMed.27882176.s7.e0" e2="DDI-PubMed.27882176.s7.e2" /><pair ddi="false" e1="DDI-PubMed.27882176.s7.e1" e2="DDI-PubMed.27882176.s7.e1" /><pair ddi="false" e1="DDI-PubMed.27882176.s7.e1" e2="DDI-PubMed.27882176.s7.e2" /></sentence><sentence text=" The activity of glutathione peroxidase (GPX) was determined in the whole blood, whereas the activity of glutathione reductase (GR) and the total antioxidant status (TAS) were determined in the serum"><entity charOffset="17-28" id="DDI-PubMed.27882176.s8.e0" text="glutathione" /><entity charOffset="105-116" id="DDI-PubMed.27882176.s8.e1" text="glutathione" /><pair ddi="false" e1="DDI-PubMed.27882176.s8.e0" e2="DDI-PubMed.27882176.s8.e0" /><pair ddi="false" e1="DDI-PubMed.27882176.s8.e0" e2="DDI-PubMed.27882176.s8.e1" /></sentence><sentence text=" The results demonstrated that concomitant administration of atorvastatin with fluoxetine caused an increase in the GPX activity and the TAS"><entity charOffset="61-73" id="DDI-PubMed.27882176.s9.e0" text="atorvastatin" /><entity charOffset="79-89" id="DDI-PubMed.27882176.s9.e1" text="fluoxetine" /><pair ddi="false" e1="DDI-PubMed.27882176.s9.e0" e2="DDI-PubMed.27882176.s9.e0" /><pair ddi="false" e1="DDI-PubMed.27882176.s9.e0" e2="DDI-PubMed.27882176.s9.e1" /></sentence><sentence text=" Atorvastatin administered to rats with paroxetine increased the activities of GPX and GR"><entity charOffset="1-13" id="DDI-PubMed.27882176.s10.e0" text="Atorvastatin" /><entity charOffset="40-50" id="DDI-PubMed.27882176.s10.e1" text="paroxetine" /><pair ddi="false" e1="DDI-PubMed.27882176.s10.e0" e2="DDI-PubMed.27882176.s10.e0" /><pair ddi="false" e1="DDI-PubMed.27882176.s10.e0" e2="DDI-PubMed.27882176.s10.e1" /></sentence><sentence text=" In the groups of rats receiving atorvastatin or SSRIs separately, no statistically significant changes in the investigated parameters were observed"><entity charOffset="33-45" id="DDI-PubMed.27882176.s11.e0" text="atorvastatin" /></sentence><sentence text=" The changes that were detected may indicate an increase in endogenous antioxidant levels during the concomitant application of atorvastatin with SSRIs and thus a drug-drug interaction having an effect on the blood redox equilibrium"><entity charOffset="128-140" id="DDI-PubMed.27882176.s12.e0" text="atorvastatin" /></sentence><sentence text="" /></document>